UK: Oxford vaccine goes to human trials' next phase

Henrietta Brewer
May 23, 2020

"Although the numbers were limited, it was really quite good news because it reached and went over an important hurdle in the development of vaccines", he said during a CNN "town hall" Thursday evening.

Andrew Pollard, the head of the Oxford Vaccine Group, said: "The clinical studies are progressing very well and we are now initiating studies to evaluate how well the vaccine induces immune responses in older adults, and to test whether it can provide protection in the wider population".

Now scientists want to recruit more than 10,000 people across the country for phases two and three, which involve vastly increasing the number of volunteers and expanding the age range to include older adults and children.

To assess whether the vaccine works, Oxford's statisticians will compare the number of infections in the control group to the number of infections in the vaccinated group.

Epoch Times

British researchers testing an experimental vaccine against the new coronavirus are moving into advanced studies and aim to immunize more than 10,000 people to determine if the shot works.

Phase one, which began in April, involved just over 1,000 adult volunteers aged 18-55, being inoculated, following promising results on six monkeys in the U.S. in late March.

The goal is to assess the immune response in people of different ages, and see if there are any differences in how the young and old react to the vaccine.

Production of the vaccine has already been scaled up ahead of the trial to prepare as early as possible for potential future deployment.

ChAdOx1 nCoV-19 is made from a weakened version of a common cold virus from chimpanzees that has been genetically changed to make it impossible for it to grow in humans. Health Secretary Alex Azar described the deal as a "major milestone" in US President Donald Trump's program to fast-track a Covid-19 vaccine, dubbed Operation Warp Speed.

"If transmission remains high, we may get enough data in a couple of months to see if the vaccine works, but if transmission levels drop, this could take up to 6 months".

Now the most valuable company on Britain's blue-chip FTSE 100 Index, AstraZeneca has already agreed to deliver 100 million doses to people in Britain, with 30 million as soon as September.

Adding: "There is uncertainty about how many cases there will be in the next three months".

The vaccine was originally developed against MERS, the last coronavirus to jump from animals to humans.

Fauci called Moderna's vaccine data "quite promising" and "better than we thought" in an interview with NPR on Friday morning.

Other reports by iNewsToday